Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Heidelberg Pharma AGXTER:HPHA -1.92%32 Current Ratio is 5.29 as of May. 2026, which is 98% above its 10-year median of 2.67. GuruFocus rates XTER:HPHA with a GF Score™ of 32/100 and a GF Value™ of €2.87 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,411 Biotechnology companies, Heidelberg Pharma AG ranks worse than 63.29% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Heidelberg Pharma AG's current ratio for the quarter that ended in May. 2026 was 5.29.
Heidelberg Pharma AG has a current ratio of 5.29. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Heidelberg Pharma AG's Current Ratio or its related term are showing as below:
XTER:HPHA'
s Current Ratio Range Over the Past 10 Years
Min: 0.2 Med: 2.67 Max: 8.12
Current: 2.4
During the past 13 years, Heidelberg Pharma AG's highest Current Ratio was 8.12. The lowest was 0.20. And the median was 2.67.
XTER:HPHA's Current Ratio is ranked worse than 63.29% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs XTER:HPHA: 2.40
Heidelberg Pharma AG (XTER:HPHA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Heidelberg Pharma AG Current Ratio Related Terms
Heidelberg Pharma AG Current Ratio Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:HPHA vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Current Ratio distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heidelberg Pharma AG (XTER:HPHA) has a Current Ratio of 5.29 as of May. 2026. This is 98% above median its historical median of 2.67. Over the past decade, Heidelberg Pharma AG's Current Ratio has ranged from 0.20 to 8.12. According to the industry distribution chart, Heidelberg Pharma AG ranks #893 out of 1411 companies in the Biotechnology industry, placing it in the top 63.3%.
Is Heidelberg Pharma AG's Current Ratio too high?
Heidelberg Pharma AG's current Current Ratio of 5.29 is 98% above median its 10-year median of 2.67. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 8.12. The Biotechnology industry median Current Ratio is 3.88. Heidelberg Pharma AG's value of 5.29 is 36.3% above this industry median. Based on the distribution chart, Heidelberg Pharma AG ranks #893 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Heidelberg Pharma AG has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #893 out of 1411 companies for Current Ratio. This places Heidelberg Pharma AG in the lower half of its industry. The industry median Current Ratio is 3.88. Heidelberg Pharma AG's value of 5.29 is 36.3% above this benchmark. Historically, Heidelberg Pharma AG's own Current Ratio has ranged from 0.20 to 8.12 over the past decade. While the company's 10-year median is 2.67 vs. the industry median of 3.88, Heidelberg Pharma AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Heidelberg Pharma AG's current Current Ratio of 5.29 is 36.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Heidelberg Pharma AG's current Current Ratio is 5.29, which is 98% above median its own 10-year median of 2.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (XTER:HPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.87, compared to a current price of €2.55 — trading 11.1% below its estimated fair value. The current Current Ratio is 5.29, which is 98% above median its 10-year median of 2.67 and 36.3% above the Biotechnology industry median of 3.88. Heidelberg Pharma AG's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Heidelberg Pharma AG (XTER:HPHA), the current Current Ratio is 5.29 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heidelberg Pharma AG (XTER:HPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued.
The current stock price of €2.55 is trading 11.1% below its estimated GF Value™ of €2.87.
GuruFocus considers Heidelberg Pharma AG to be Significantly Overvalued.
Key valuation signals for XTER:HPHA:
Current Ratio: 5.29 (98% above median its 10-year median of 2.67)
GF Value™: €2.87 vs. price of €2.55 (11.1% below fair value)
Industry Position: 36.3% above the Biotechnology median (#893 of 1411)
No single metric tells the full story. See the XTER:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
32GF Score
Get the complete analysis for XTER:HPHA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:HPHA has been successfully added to your 
